Zdrowie i gospodarka · 19/02/2016

FDA Releases Guidance on Immunogenicity-Related Considerations for Low Molecular Weight Heparin

The Food and Drug Administration (FDA) has made available a guidance document for industry that outlines considerations for low molecular weight heparin (LMWH) products, focusing on impurities and their potential effects on immunogenicity.